Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.S1 Biopharma, an early-stage biopharmaceutical company, has announced its foray into male sexual health with S1P-205, the drug in development to treat Hypoactive Sexual Desire Disorder (HSDD) in males.
Subscribe to our email newsletter
With the development of S1P-205, the company is taking steps to address desire disparity between partners and dispelling the myth than men don’t have problems with desire.
S1 Biopharma chief medical officer Robert E. Pyke said,"PDE-5 inhibitor therapies are only half the story, and we hope to address the other half with S1P-205, helping men and their partners to have more fulfilling relationships."
S1 Biopharma CEO Nicolas G. Sitchon said, "S1P-205 and Lorexys, our drug for female HSDD, are perfect for this dual treatment approach."